👋 Good morning! Novo Nordisk has spent the past few years turning semaglutide into one of the most successful drug franchises in pharmaceutical history. Ozempic and its sister products reshaped the obesity and diabetes markets and pushed the company into the center of the global GLP-1 boom.

Now the FDA would like to talk about the paperwork.

Regulators recently issued Novo a warning letter after inspectors found the company failed to properly investigate and report several serious adverse events tied to Ozempic. The incidents included two deaths and one case of completed suicide, but the agency’s primary concern was how the events were reported.

According to the FDA, Novo missed required 15-day reporting deadlines and failed to submit safety reports for at least ten serious adverse events. Some were filed more than 800 days late. Investigators also said the company’s own procedures for post-market safety monitoring actually complicated the reporting process.

Novo says it is cooperating with regulators and addressing the findings. Still, the warning letter adds another regulatory wrinkle for the company’s blockbuster GLP-1 franchise.

When millions of patients are taking the same drug, the FDA expects the safety paperwork to move almost as fast as the prescriptions.

💰 Lilly Pumps $3B Into China as Oral Obesity Race Heats Up
Eli Lilly is committing $3 billion over the next decade to expand manufacturing and supply chains in China as it prepares for a potential launch of its oral obesity drug orforglipron. The small-molecule GLP-1 pill is currently under FDA review with a decision expected in April, and Lilly has also filed for approval with Chinese regulators. The investment will expand local production capacity and help build a domestic supply chain for the drug. In parallel, Lilly pledged $500 million to support South Korea’s biopharma ecosystem, including a new Gateway Labs incubator developed with Samsung Biologics. Translation: Lilly is building the obesity drug infrastructure before the pill even hits pharmacy shelves.

⚠️ Stryker Hit by Cyberattack Linked to Pro-Iran Hacker Group
Medical technology giant Stryker suffered a sweeping cyberattack that wiped data across portions of its global network and temporarily locked employees out of computers and smartphones. The group Handala, which claims ties to pro-Iran activism, took credit and said it deleted and extracted information from more than 200,000 systems. Employees were instructed to disconnect company hardware from the internet and remove work profiles from phones while login screens displayed the group’s logo. Even the company’s Michigan headquarters temporarily shut down operations as a precaution. For a company whose products operate inside hospitals worldwide, cybersecurity just became a very real operational risk.

🏃 Vertex’s Kidney Drug Impresses Analysts, Filing Sprint Begins
Vertex reported positive phase 3 data for its IgA nephropathy drug povetacicept, cutting protein levels in urine by nearly 50 percent compared to placebo at a 36-week interim analysis. The therapy targets BAFF and APRIL signaling pathways involved in autoimmune kidney damage. With the primary endpoint achieved, Vertex plans to submit its FDA filing by the end of March. Analysts now estimate roughly a 90 percent probability of approval, potentially arriving later this year.

🏭 Sandoz Spins Up Dedicated Biosimilars Unit for Patent Cliff Era
Sandoz is reorganizing its business to focus aggressively on biosimilars, launching a standalone unit dedicated to development, manufacturing and supply of copycat biologic medicines. The move reflects what the company calls a coming “golden decade” as biologic drugs worth more than $650 billion lose patent protection over the next ten years. The company estimates roughly $322 billion in biosimilar opportunities could emerge for them during that period.

🧠 FDA Clears Old GSK Drug for Ultra-Rare Brain Disease.
Wellcovorin was approved for cerebral folate transport deficiency instead of autism, a condition affecting fewer than 50 documented patients.

🔬 Agilent Buys Pathology Firm for $950M.
The diagnostics company will acquire Biocare Medical to expand its cancer testing portfolio built around immunohistochemistry and molecular pathology tools.

🧬 BioNTech Founders Launch New mRNA Venture.
CEO Uğur Şahin and CMO Özlem Türeci are launching a new startup focused on next-generation mRNA technologies.

✂️ Evotec Plans 800 Job Cuts.
The German drug discovery company will eliminate roughly one-sixth of its workforce as part of a broader restructuring effort.

🏭 CSL Expands $1.5B Plasma Facility in Illinois.
The project will boost production of plasma-derived therapies and add hundreds of jobs over the next decade.

⚖️ Senate Investigation Targets FDA Rare Disease Decisions.
Lawmakers say they may subpoena documents tied to several recent drug rejection controversies.

💸 Medtronic Buys Stroke Device Maker for $550M.
The Scientia Vascular acquisition adds specialized guidewires and microcatheters used to remove clots deep in the brain.

When lawmakers debate federal research spending, the discussion usually centers on cost. A new economic analysis suggests the more interesting number might be the return.

According to a report from United for Medical Research, NIH funding generated roughly $94 billion in economic activity in 2025 while supporting nearly 391,000 jobs across the United States. That impact came from about $36.6 billion in research funding, which translates to roughly $2.57 in economic output for every federal dollar invested.

The numbers also show how the funding landscape is shifting. Because of delays tied to budget uncertainty and leadership changes, the NIH fell behind schedule distributing grants last year. To catch up, the agency relied more heavily on multi-year awards, issuing fewer grants overall but making each one larger. The total number of grants dropped by more than 5,500 compared with the previous year, while the average award size climbed to more than $622,000.

Competition for funding continues to intensify as well. The NIH grant success rate fell to about 17 percent, the lowest level in three decades, meaning most research proposals never receive funding. Even so, the broader economic impact remains enormous. Over the past decade NIH funding has generated more than $822 billion in economic activity and supported millions of jobs.

Separate analyses show hundreds of FDA-approved drugs benefited from NIH-supported research during that period, reinforcing how often therapies that eventually reach the market begin in federally funded laboratories.

That is how much Eli Lilly paid CEO David Ricks in total compensation last year. The number reflects a period of extraordinary growth for the company, driven largely by its GLP-1 drugs Mounjaro and Zepbound. Together the therapies generated more than $36 billion in annual sales and helped push Lilly’s market value above $1 trillion, making it the first pharmaceutical company to reach that milestone.

Here’s what biotech Redditors are talking about:

💼 Thermo Fisher… Director title, analyst salary
A Reddit thread asked whether Thermo Fisher is known for lowballing job offers. Commenters widely agreed the company often pairs inflated job titles with modest compensation, which explains why many early-career scientists suddenly become “Directors” on LinkedIn. Several users also mentioned benefits and PTO packages lagging competitors.

😩 Has biotech ever been this unstable?
Another scientist finishing a postdoc asked whether the biotech job market has ever been this crowded for entry-level roles. Replies blamed a mix of higher interest rates, the post-pandemic biotech reset and broader skepticism toward science funding. Some industry veterans pointed out that the early 2000s were similarly difficult after the dot-com crash. Still, many commenters argued the current market feels unusually competitive, with thousands of applicants often competing for a single role.

🧬 New Gene Editing Tool Inserts Large DNA Segments.
Researchers demonstrated a technique using circular single-stranded DNA that could enable safer large-scale genome edits.

⌚️ ARPA-H Launches Wearable Biosensor Program.
The Delphi initiative aims to develop low-cost sensors capable of continuously monitoring biological signals.

🧫 Bacteria-Based Cancer Therapy Heads Toward IPO.
Salspera plans to raise $91 million to fund late-stage testing of a salmonella-derived immunotherapy.

🤖 Breakout Ventures Launches $114M AI Science Fund.
The firm will back startups combining artificial intelligence with deep scientific discovery platforms.

🏋 Vima Therapeutics Raises $100M to Restore Movement
Vima Therapeutics has raised $100 million to advance its oral neurological drug VIM0423 into mid-stage clinical trials for Parkinson’s disease and dystonia. The therapy targets muscarinic cholinergic receptors involved in motor control, with the goal of restoring smoother movement in patients whose neural signaling has been disrupted. The startup emerged from Atlas Venture and plans to begin larger trials soon, with clinical readouts expected in 2027.

🦠 March 12, 2003 — The World Meets SARS
On this day the World Health Organization issued a global alert about a mysterious respiratory illness that would become known as Severe Acute Respiratory Syndrome (SARS). The virus ultimately infected more than 8,000 people across multiple countries before the outbreak was contained in 2004. Researchers later traced the pathogen to horseshoe bats, with civets acting as an intermediate host before it spread to humans.

If the NIH numbers prove anything, it is that basic research tends to pay off eventually. Sometimes it produces a breakthrough therapy. Sometimes it launches a billion-dollar biotech startup. And occasionally it quietly lays the groundwork for the next medical breakthrough years before anyone realizes it.

Turns out the world’s most patient venture fund might still be the federal government.

That’s all for today. See you Tuesday for the next issue. 👋

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead